A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection

We generated an optimized COVID-19 vaccine candidate based on the modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein, termed MVA-CoV2-S(3P). The S(3P) protein was expressed at higher levels (2-fold) than the non-stabilized S in cell...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Patricia Pérez, Adrián Lázaro-Frías, Carmen Zamora, Pedro J. Sánchez-Cordón, David Astorgano, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-01-01
coleção:	Frontiers in Immunology
Assuntos:	SARS-CoV-2 vaccine MVA vector prefusion-stabilized S protein protective efficacy mouse model
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.824728/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!